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Background: Previously, Huangqi decoction (HQD) has been found to have a potential therapeutic effect on DMN-
induced liver cirrhosis. Here, the mechanisms of HQD action against liver fibrosis were investigated in relation to
hepatocyte apoptosis and hepatic inflammation regulation.
Methods: Liver fibrosis was induced by DMN administration for 2 or 4 weeks. Hepatocyte apoptosis and of Kupffer
cells (KC) and hepatic stellate cells (HSC) interaction were investigated using confocal microscopy. The principle
cytokines, fibrogenic proteins and apoptotic factors were investigated using western blot analysis.
Results: Compared with the DMN-water group, HQD showed decreased hepatocyte apoptosis and reduced
expression of apoptotic effectors, cleaved-caspase-3, and fibrotic factors, such as smooth muscle α-actin (α-SMA),
transforming growth factor beta-1 (TGF-β1). However, the KC marker CD68 increased significantly in DMN-HQD
liver. Confocal microscopy demonstrated widespread adhesion of KCs to HSCs in DMN-water and DMN-HQD rats
liver.
Conclusions: HQD exhibited positive protective effects against liver fibrosis; its mechanism of action was associated
with protection from hepatocyte apoptosis and the promotion of CD68 expression in the devolopment of liver
fibrosis to cirrhosis development.Background
Fibrosis is a wound-healing response that engages a
range of cell types and mediators to encapsulate an in-
jury. During the fibrogenesis development, many patho-
logical factors, such as inflammation derived from
Kupffer cells (KCs), angiogenesis, and hepatic stellate
cell (HSC) activation, interact with each other, leading to
collagen deposition [1]. Cirrhosis, the most advanced
stage of fibrosis, includes inflammation as a pathological
factor but this aspect is remarkably reduced in fibrosis,
with septa and nodule formation being the most notable
features [2]. Understanding of the pathological factor
differences between fibrosis and cirrhosis may lead to* Correspondence: liuliver@vip.sina.com.cn
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reproduction in any medium, provided the orthe development of agents suitable for cirrhosis but not
fibrosis. All these concepts derive from the striking pro-
gress in the understanding of the biochemistry and cell
biology that underlies fibrosis and cirrhosis as a compre-
hensive pathological process involving not just a single
cell type [3].
In the past 20 years, HSCs have emerged as a well-
characterized cell type with a central role hepatic fibrosis
hepatic fibrosis [4,5]. Recent research has shown that
the microenvironment plays a key role in regulating
HSC activation [6]. KCs or resident hepatic macrophages
carry out an important role in modulating inflammation
in liver fibrosis development [7-9]. In the case of liver fi-
brosis, it has been suggested that KCs produce a variety
of proinflammatory cytokines, such as tumor necrosis
factor (TNF)-α, interleukin (IL)-1β, and macrophage in-
flammatory protein (MIP)-1, which provoke HSC activa-
tion and subsequently contribute to hepatic injury.
According to the published data, inflammation may be aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a pivotal position in fibrosis development [10].
In spite of the high incidence of hepatic fibrosis world-
wide, no generally accepted antifibrogenic therapy is avail-
able. Chinese herbal medicine has been widely used for
treating chronic liver hepatitis and liver cirrhosis for thou-
sands of years. and these treatments appear to improve
clinical symptoms, liver function and patient quality of life
[11,12]. Huangqi decoction (HQD) is a classical recipe for
treating liver injury that has a long history in traditional
Chinese medicine. HQD consists of two medicinal herbs,
Radix Astragali and Radix et Rhizoma Glycyrrhizae, mixed
in a 6/1 (wt/wt) ratio. It has been previously reported from
this laboratory that HQD exerts significant therapeutic
effects in the treatment of liver cirrhosis induced by
dimethylnitrosamine (DMN) in rats [13]. However, in an-
other study, HQD has been shown not to significantly im-
prove liver function in the process leading from fibrosis to
cirrhosis [14].
To evaluate the factors critical for DMN-induced liver
injury, the present study focused on the HQD’ effects on
hepatocyte apoptosis, fibrosis, and inflammation regula-
tion in the development of liver fibrosis to cirrhosis fol-
lowing DMN-induced liver injury.
Methods
Materials
DMN and Sirius red were purchased from Sigma-Aldrich
(Saint Louis, MO, USA). ApopTag Fluorescein in Situ
Apoptosis Detection kit (S7110) was purchased from Che-
micon International Inc. (Temecula, CA, USA). For pri-
mary antibodies used in immunostaining and western
blot, anti-caspase-3 rabbit antibody was purchased from
Cell Signaling Technology, Inc. (Danvers, MA, USA), used
at 1:1000 dilution; anti-CD68 mouse antibody purchased
from AbD Serotec (Kidlington, UK), used in 1:100 dilu-
tion; anti-TNF-a and anti-IL-1β rabbit antibodies from
Chemicon Internat. Inc., diluted to 0.2 μg/ml; anti-
MIP-1 rabbit antibody from BioVision, Inc. (Milpitas,
CA, USA), used to 0.2 μg/ml; anti-a-SMA mouse anti-
body from Sigma, used at 1:400 dilution; and anti-TIMP-1
and TIMP-2 from LabVision, Thermo Scientific, Kalamazoo,
MI, USA), diluted to 2 μg/ml. Anti-TGF-β1 was obtained
from R&D Systems, Inc. (Minneapolis, MN, USA), used at
1:1000 dilution,anti-HGF rabbit antibody from Enzo Life
Sciences, Inc. (Farmingdale, NY, USA), used in 5 μg/ml dilu-
tion; anti-glyceraldehyde 3-phosphate dehydrogenase
(anti-GADPH) mouse antibody from Kangchen Bio-
tech Inc. (Shanghai, CN) diluted by 1:5000; the sec-
ondary fluorescence-labeling goat anti-mouse FITC,
Cy3 antibody from Jackson ImmunoResearch Labora-
tories, Inc. (West Grove, PA, USA), used at 1:1000 di-
lution; and labeled goat anti-mouse isotype-specific
antibody Alexa Fluor 647 immunoglobulin G (IgG)2afrom Molecular Probes (Life Technologies, Grand Island,
NY, USA), used at 5 mg/ml.
DMN model
All procedures using animals were carried out in accord-
ance with the guidelines presented in the “Principles for
the Care and Use of Animals in the Field of Physio-
logical Sciences,” published by the Physiological Society
of China. The study protocol was approved by an ethics
committee of Shanghai University of Traditional Chinese
Medicine’s Animal Ethics Committee (Shanghai). Forty
male Wistar rats (180-200 g) were housed in an air-
conditioned room at 25°C with a 12 h light/dark cycle,
were randomized into two groups, a control (n = 10) and
a DMN-treated group (n = 30). DMN was administered
at 10 mg/kg intraperitoneally to rats for 3 consecutive
days each week for 4 weeks [15]; control rats received
equal quantities of physiological saline. At the end of the
second week, 3 and 6 rats from the control and DMN-
treated groups, respectively, were sacrificed for fibrosis
development assessment. The remaining DMN rats were
further randomized into 2 groups, a DMN-water (n = 12)
and a DMN-HQD group (n= 12). With continued weekly
DMN treatment, the rats received a daily administration
of water or HQD given intragastrically at 1 ml/100 g. At
the end of the fourth week, all animals were sacrificed and
liver samples collected for subsequent investigations.
Preparation of HQD
HQD consists of crude slices from Radix Astragali and
Radix et Rhizoma Glycyrrhizae mixed in a 6/1 ratio
(wt/wt). The herbal medicine was accredited by
pharmacognosist and prepared by Shuguang Hospital.
Specifically, the medicinal herbs mixture was extracted
in boiling water and the resulting aqueous extracts
dry-sprayed to obtain a powder and then stored at
−20°C. The extract powder was weighed and used for
experiments by dissolution in pure water at the desired
concentrations.
Histological analysis
Liver specimens were preserved in 4% paraformalde-
hyde, dehydrated in a graded alcohol series, embedded
in paraffin blocks, sectioned to 5 μm-thick slices, placed
on glass slides, and stained with Sirius red. Fibrosis was
graded according to the method by Scheuer as follows:
grade 0, normal liver; grade 1, increased collagen with-
out formation of septa (small satellite expansion of por-
tal fields); grade 2, formation of incomplete non-
interconnecting septa, from portal tract to central vein;
grade 3, complete but thin interconnecting septa, which
divide the parenchyma into separate fragments; and
grade 4, complete cirrhosis, similar to grade 3 but with
thicker septa [16]. Three pathologists blind to the rats'
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nations. Fibrosis scores were given after thorough exam-
ination of three different areas of the tissue slide from
each rat.
Hepatic hydroxyproline content
Liver tissue (100 mg) was prepared for hydroxyproline
(Hyp) determination using to a modified version of a
method developed by Jamall [17]. Hyp liver content
served as an indirect measure of tissue collagen content,
expressed as μg/g wet weight (μg/g).
Western blot analysis
Liver samples were prepared in radio immunoprecipita-
tion lysis buffer containing protease inhibitors (Mini
Protease Inhibitor Cocktail cOmplete, Roche Applied
Science, Tokyo, JP) and phenylmethylsulfonyl fluoride
(Ameresco Inc., Solon, OH, USA). After protein quanti-
fication, equal amounts of protein (50 μg/lane) were
separated by 10 or 15% polyacrylamide gel electrophor-
esis (PAGE) and transferred to Immobilon-P transfer
membranes (Millipore, Billerica, MA, USA), which were
then blocked and exposed to antibodies. The antigens
were visualized using an ECL kit for 1 min followed by ex-
posure to Kodak film.
Immunohistochemical staining
After deparaffinization and dehydration, microwave anti-
gen retrieval was performed for 5 min prior to peroxid-
ase quenching with 3% H2O2 in phosphate buffered
saline (PBS) for 15 min. Subsequently, sections were pre-
blocked with 5% bovine serum albumin (BSA) for
30 min and incubated with a primary antibody (anti-
HGF, diluted to 5 μg/ml in PBS) overnight at 4°C. A
negative control was treated as the other samples except that
primary antibodies were replaced with PBS and no staining
took place. After washing in PBS, sections were incubated
with biotinylated secondary antibody for 30 min and then
stained with 3,3’-diaminobenzidine (Vector Laboratories,
Inc., Burlingame, CA, USA) for 2–5 min. Slides were finally
counterstained with hematoxylin for 2–3 min, mounted, and
examined.
Gelatinase activity assay
Liver proteins (50 μg/lane) were electrophoresed in 10%
sodium dodecyl sulfate (SDS)-PAGE containing 0.1% gel-
atin (Sigma-Aldrich), the SDS removed by soaking the gels
in buffer containing 50 mM Tris (pH 7.6), 10 mM CaCl2,
and 2.5% Triton X-100 (Sinopharm Chemical Reagent
Co., Ltd, Shanghai, CN) for 20 min, followed by the same
buffer containing 1% Triton X-100. Digestion was allowed
to occur at 37°C for 24 h and gels then stained with Coo-
massie brilliant blue and destained until clear bands be-
came evident.Immunofluorescence staining
Liver samples were excised, and immersed immediately
in cryomatrix (Tissue-Tek OCT, Sakura Finetek USA,
Inc., Torrance, CA, USA), and flash-frozen in liquid ni-
trogen; sectioned to 5 μm slices, and mounted on slides.
Slides were then incubated in 5% BSA for 30 min and
followed by incubation with primary antibody (anti-α-
SMA, CD68) at 37°C for 1 h. Slides were then washed 3
times with PBS and incubated with secondary antibody
for 30 min.
Confocal microscopy for detection of hepatocyte
apoptosis detection and KC and HSC interactions
First, terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) assay were performed using a
commercially available kit (Chemicon, Internat. Inc.) follow-
ing the manufacturer’s instructions. then, slides were incu-
bated in 5% BSA for 30 min, and followed by incubation
with primary antibody (anti-Heppar) at 37°C for 1 h.washed
3 times with PBS and they were incubated with secondary
antibody (Cy3-conjugated affinipure goat anti-mouse) for
30 min.
For double-color labeling of CD68 and α-SMA, liver sec-
tions were incubated with monoclonal anti-CD68 for 1 h at
room temperature, biotin-conjugated anti-mouse IgG1
(A85-1, BD Pharmingen Inc., San Diego, CA, USA) was
then added, and the mixture was incubated for 30 min.
The staining reaction was developed with a Cy3-conjugated
streptavidin incubation for 30 min and, after washing, the
sections were incubated with α-SMA antibody followed by
Alexa Fluor 647-labeled goat anti-mouse isotype-specific
antibody and then covered with mounting medium.
Statistical analysis
All results were expressed as mean and standard deviation.
Measurement data were analyzed using a one-way analysis
of variances (ANOVA, SPSS, Inc., Chicago, IL, USA). Rank
data were analyzed with ridit. Groups were compared using
ANOVA with Dunnett’s multiple comparison test. Results
with p<0.05 were considered to be statistically significant.
Results
HQD inhibited HSC activation but did not significantly
affect collagen content in DMN livers
Observations of Sirius red staining showed that collagen
was scarce except around small central venous walls in
control liver (Figure 1A). In DMN-treated livers at 2 weeks,
collagen was seen to stretch from the portal area to lobular
areas, and incomplete septa were also observed. In DMN-
water liver, cirrhotic nodule formation was observed and,
in comparison, collagen deposition was decreased to a cer-
tain extent in DMN-HQD liver. Ridit analysis showed that
the DMN-HQD rats were not significantly different from
the DMN-water rats (p>0.05). (Table 1).
Figure 1 Effects of Huangqi decoction (HQD) on histological changes (A, Sirius Red staining original magnification× 100; B, α-SMA
staining original magnification × 100), C, hydroxyproline content, and D, the expression of pro-fibrotic factors of rat livers in DMN-
induced liver fibrosis. ▲ p< 0.05, ▲▲p< 0.01, vs. DMN-water rats; 5p< 0.05, 55p< 0.01 vs. 2 weeks DMN rats. Western blot analysis of total
protein extracts was performed by antibodies recognizing α-SMA, TIMP-1, TGF-β1 and GAPDH respectively. Results are mean± SD.
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progression in a quantitative manner was evaluated by
measuring liver Hyp content. HQD was not found to de-
crease liver Hyp content significantly (p>0.05, Figure 1C).
As sustained deposition of extracellular matrix resultes
mainly from HSC activation, a correlation betweenTable 1 Effects of HQD on fibrotic grade and hydroxyproline




Control 10 179.36 ± 31.29▲▲55 10
2 weeks DMN 6 289.06 ± 66.00▲▲ 0
DMN-water 12 641.71 ± 187.8155 0
DMN-HQD 12 559.04 ± 163.02 0
grade 0: normal; grade 1: very slight; grade 2: slight; grade 3: moderate; grade 4: se
P < 0.05 P < 0.01 (vs DMN- water) P < 0.05 P < 0.01 (vs 2 weeks DMN).accumulated collagen and activated HSCs was studied
by detecting a-SMA, a marker of activated HSC, immu-
nohistochemically in liver sections, as described above.
Vascular smooth muscle cells were positive for α-SMA
in control liver (Figure 1B). α-SMA+ HSCs were detected
in periportal fibrotic bands in 2-week DMN liver, with the(Hyp) content in DMN-induced liver fibrosis of rats
rade Confidence
intervalI II III IV
0 0 0 0 (-0.110,0.228)▲▲55
0 4 2 0 (0.051,0.486)▲▲
0 0 3 9 (0.586,0.894)55
0 0 8 4 (0.580,0.734)
vere. Data are expressed as numbers of animals with each fibrotic grade.
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4-week DMN-water cirrhotic liver. In contrast, a marked
reduction of α-SMA+ HSCs was observed in DMN-HQD
liver, compared with DMN-water liver.
Altered expression of α-SMA in DMN-treated liver sam-
ples was also detected by western blot analyses (Figure 1D).
The expression of transforming growth factor (TGF)-β1, tis-
sue inhibitor of metalloproteinases (TIMP)-1, and TIMP-2
increased gradually following DMN treatment and
these trends were almost identical with that of α-SMA.
Compared to DMN-water liver, HQD administration
resulted in marked reductions in TGF-β1 and TIMP-1/2,
and control rats expressed little active matrix metalloprotei-
nases (MMP)-2/9 (Figure 1D). Following DMN treatment,
activities of these enzymes were increased significantly and,
in addition, less intense bands of 66 kD were present in
zymograms of liver protein from DMN-water treatment,
which corresponded to partially or completely activated
forms of MMP-2. In contrast, treatment with HQD showed
reductions in MMP-2/9 activity.
Taken together, these results confirmed that DMN admin-
istration caused HSC activation and increased production
and accumulation of extracellular matrix, which might have
facilitated or resulted in liver fibrosis and cirrhosis in DMN-
treated rats. HQD remarkably decreased α-SMA+ HSCs,
whereas HQD did not significantly reduce collagen content.
HQD was reduced on hepatocyte apoptosis and
pro-apoptotic factors
The fact that, in rat liver, HQD significantly inhibited HSC
activation but did not significantly decrease collagen was
puzzling. As liver fibrosis is a complex process resulting from
hepatocyte apoptosis, inflammation, and HSC activation, inFigure 2 Effects of HQD on hepatocyte apoptosis (A), caspase-3 and H
cryosections were stained with TUNEL (green) and hepatocytes paraffin an
means hepatocyte apoptosis. The arrows with blue color indicate apoptoti
apoptosis. (Original magnification× 400).liver fibrosis development, hepatocyte apoptosis and KC and
HSC interactions lead to fibrosis. Thus, some important fac-
tors involved in these processes were detected here.
DMN is known to induce hepatocyte apoptosis [18,19].
Here, hepatocyte apoptosis was studied using confocal mi-
croscopy characterized by hepatocyte paraffin antigen (Hep-
par, a hepatocyte marker) with TUNEL. The results showed
that hepatocyte apoptosis was rarely observed in control
liver (Figure 2A), but there were clear apoptotic hepatocytes
detected in 2-week DMN liver. In 2- or 4-week DMN liver,
there were a few hepatocyte apoptoses as well as some other
apoptotic cells and , HQD inhibited hepatocyte apoptosis.
The expression of Bax and caspase-3 was found to be sig-
nificantly increased following 2 weeks of DMN treatment
(Figure 2B) and decreased in DMN-water liver. HQD ad-
ministration resulted in significant reductions in cleaved-
caspase-3 and Bax expression, compared with DMN-water
liver. HGF-α expression decreased gradually following DMN
administration (Figure 2B), and compared with DMN-water
liver, HQD remarkably increased HGF-α expression.
Effects of HQD on proinflammatory factors such as CD68,
TNF-α, IL-1β, and MIP-1α
Liver inflammation can be associated with KC activation
and trigger migration of “professional” phagocytes into hep-
atic cords where these macrophages stimulate fibrosis by
secreting proinflammatory cytokines. To elucidate the roles
of KCs in DMN-induced liver fibrosis, a specific KC mar-
ker, CD68, has been used to monitor KC activation [20].
Here, CD68+ KCs were observed in hepatic sinusoid
while they were extremely low in control liver (Figure 3A).
After 2 weeks of DMN administration, strongly stained
CD68+ KCs not only appeared in hepatic sinusoid, butGF expression (B) in DMN-induced liver fibrosis in rats. Hepatic
tigen (Heppar, red). TUNEL (green) located in or near Heppar (red)
c hepatocytes, the arrows with white color indicate non-hepatocyte
Figure 4 Effects of HQD on interaction of KCs and HSCs in
DMN-induced liver fibrosis in rats. Hepatic cryosections were
stained with α-SMA (blue) and CD68 (red). The pink color means the
colocalization of (CD68) KCs and (α-SMA) HSCs. (Original
magnification × 200).
Figure 3 Effects of HQD on CD68 using immunofluorescence staining (A) and the expression of pro-inflammatory factors (B) using
western blot analysis in DMN-induced liver fibrosis. Western blot analysis of total protein extracts was performed by antibodies recognizing
CD68, TNF-α, MIP-1, IL-1, and GAPDH respectively. CD68, red; DAPI, blue; (original magnification × 200).
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mainly located in the fibrotic band and portal area in
DMN-water liver. HQD was found to increase CD68+ KCs
expression in fibrotic septa, results similar to those were
obtained from western blot analysis (Figure 3B).
Compared with control liver, CD68 expression increased
dramatically with 2-week DMN liver (Figure 3B). CD68
decreased significantly in 4-week DMN-water liver com-
pared with 2–week DMN liver, and significantly increased
in DMN-HQD compared with 4-week DMN-water liver
(Figure 3B). The expression trends of TNF-α, IL-1β and
MIP-1α were almost identical with that of CD68, which
indicated that, here, CD68+ KCs were the major source of
hepatic proinflammatory responses.
Effect of HQD on KC and HSC interaction
The pathophysiological involvement of KCs in DMN-
induced liver fibrosis was elucidated by observation of
colocalized CD68 and α-SMA using confocal microscopy.
From double-color immunofluorescence staining, CD68+
KCs were observed neighboring or directly adhered to the
α-SMA+ HSCs in the sinusoid or portal area in 2-week
DMN liver, while both cell types were not observed in
control liver (Figure 4). Similar results were also observed
in 4-week DMN-water liver. HQD was found to reduce α-
SMA expression but also to increase CD68 expression. In
addition, widespread KC to HSC adhesion was observed
in thick fibrotic bands in DMN-HQD liver. These results
collectively demonstrated that KCs played a key role in in-
flammation and fibrosis from DMN-induced liver injury.
Discussion
The present study demonstrated that HQD ameliorated liver
fibrosis to some extent and in a comprehensive manner.HQD exerted a beneficial anti-apoptotic influence and sig-
nificantly inhibited fibrotic-related factors remarkably. How-
ever, it increased the expression CD68 and proinflammatory
cytokines in the presence of DMN-induced liver fibrosis.
These results indicated that KC activation and inflammation
played a key role in the process of liver fibrosis to cirrhosis
development.
DMN-induced liver fibrosis in rats is a reproducible
model for studying the pathogenesis of liver fibrosis and
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ture of many liver diseases and is thought to play a role in
initiating and maintaining HSC activation. Apoptosis of
parenchymal cells is no longer viewed a silent conse-
quence of liver injury, but rather as an important inflam-
matory stimulus that activates stellate cells, which display
a surprising capacity to phagocytize apoptotic bodies.
Thus, efforts to block hepatocyte apoptosis therapeutically
are being developed as a potential antifibrotic strategy.
HGF is a pluripotent growth factor displaying a remark-
able ability to promote tissue repair and organ regener-
ation after injury. and indeed appears to ameliorate
fibrosis and cirrhosis in animal models [23-26]. Three dif-
ferent mechanisms have been proposed for HGF's antifi-
brotic effects. One is the prevention hepatocyte apoptosis
and stimulation of hepatocyte mitosis in DMN-induced
liver fibrosis, resulting in the survival of rats with an
otherwise lethal illness. the second is an increase in hep-
atic collagenase activity that promotes degradation of the
extracellular matrix (ECM) components. The third path-
way is the reduced expression of of mRNA for procolla-
gens and TGF-β1. the latter being a crucial factor in liver
fibrosis and a potent inhibitor of hepatocyte growth. It has
been demonstrated that HGF antagonizes TGF-β1 dir-
ectly, improving liver regeneration by inhibiting TGF-β1
expression [23]. The specific mechanism responsible for
improved liver functional capacity with HGF remains un-
clear. but recently observations have suggested that HGF is
a potent anti-inflammatory cytokine that inhibits renal in-
flammation by disrupting nuclear factor (NF)-κB signaling
and can be a promising therapeutic agent for progressive
renal diseases. The present data showed that HGF decreased
gradually during the course of DMN-induced liver fibrosis.
In contrast, HGF-α expression in DMN-HQD liver was
increased significantly compared to DMN-water liver.
Liver fibrosis is traditionally viewed as a progressive
pathological process involving multiple cellular and mo-
lecular events that ultimately lead to deposition of excess
matrix proteins in the extracellular space [27]. Studies with
both animal and human fibrogenesis have demonstrated a
positive correlation between the degree of fibrosis and
HSC activation in damaged liver [28]. Activated HSCs are
characterized by a high rate of proliferation, the expression
of fibrotic cell markers such as α-SMA, and the production
of ECM. In the present study, western blotting and im-
munofluorescence staining of α-SMA showed that HSCs
were activated in DMN-induced liver fibrosis and that
HQD significantly suppressed HSC activation significantly.
From the current therapeutic point of view, suppression
of hepatocyte apoptosis and profibrogenic factors and
increases in HGF expression are critical in the prevention
of fibrosis onset and progression. As here HQD increased
HGF-α expression, decreased cleaved-caspase-3 expression,
and suppressed α-SMA expression, HQD exhibited bothanti-apoptotic and fibrinolytic potential, as described
above. Thus, HQD appears to be an ideal therapeutic
agent for liver fibrosis treatment. However, the hydroxy-
proline assays and histological evaluations demonstrated
that HQD had certain but not notable effects in DMN-
induced liver fibrosis. Taken together these results indi-
cated there were some more important pathological fac-
tors involved in DMN-induced liver fibrosis.
KCs synthesize a variety of mediators, such as proin-
flammatory cytokines and reactive oxygen species, and
fulfill a crucial role in the liver immune response [29-31].
In the chronic inflammatory milieu, KCs interact with
other cell types, including fibroblasts that transdifferenti-
ate into matrix-secreting myofibroblasts, with resultant
scar-tissue formation and disruption. Accumulating evi-
dence has suggested that KCs play a key role in regulating
HSC activation and function, and thus, a thorough our
understanding of the complex interplay between chronic
inflammation and progressive fibrosis is a critical step to-
ward the rational design of new treatments; several studies
have evaluated the role of conditioned medium from KCs
in stimulating HSCs [32,33]. However, to date there has
been limited available information regarding the inter-
action of KCs and HSCs in vivo. Meanwhile cell culture
(in vitro) does not properly reflect the complexity of
microenvironment in vivo, and interaction or microenvir-
onment in vivo should be considered the gold standard
for the study of HSC and KC biology. The results from
double-color confocal evaluation of CD68 and α-SMA,
results showed that KCs were located adjacent to or dir-
ectly interacting with α-SMA-positive HSCs in the DMN-
water liver, indicating that KC activated HSC in fibrotic
septa. HQD reduced α-SMA expression but increased
CD68 expression, such that HQD did not inhibit the inter-
action of KCs and HSCs. From these results, it was con-
cluded that KCs or inflammation played a vital role in
regulating fibrogenesis in DMN-induced liver fibrosis.
In summary, the present observations demonstrated that
HQD suppressed expression of HSC activation and hepato-
cyte apoptosis, while also increasing HGF-α expression.
However, it did not suppress the expression of proinflamma-
tory factors, such ad CD68 and TNF-α. The results clearly
indicated that KCs played a vital role in DMN-induced liver
fibrosis and, collectively, augment the understanding of the
mechanism of hepatic fibrosis. In addition, they might pro-
vide potential for the development of therapeutic manipula-
tions for modulating fibrosis through the suppression of KC
activation and proinflammatory cytokines.
Conclusion
HQD has favorable ameliorating effects against liver fibrosis;
its mechanism of actions was associated with protection from
hepatocyte apoptosis and promotion of CD 68 expression in
the development of liver fibrosis to cirrhosis development.
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